Published • loading... • Updated
Definium Says LSD-Based Pill Reduces Anxiety in Late-Stage Study
The company said the treatment produced a 5.4-point placebo-adjusted improvement on a standard anxiety scale and was generally well tolerated.
- Definium Therapeutics announced on Wednesday that its Phase 3 'Voyage' study of the LSD-based experimental pill DT120 met its primary goal, significantly reducing anxiety symptoms in adults with generalized anxiety disorder.
- Generalized anxiety disorder affects approximately 26 million U.S. adults, yet the last new FDA-approved treatment for the condition occurred nearly two decades ago, creating significant unmet clinical need.
- The 214-patient trial showed participants receiving the 100-microgram DT120 dose experienced an 11.6-point reduction on the Hamilton Anxiety Rating Scale at week 12, compared to a 6.2-point drop for the placebo group.
- Following the announcement, shareholders pushed the company's stock up 15% to just over $47 apiece at market open Wednesday, though the share price settled around $43 by mid-morning.
- Definium expects a second Phase 3 trial called 'Panorama' to produce data in September; Evercore ISI analyst Gavin Clark-Gartner models $2 billion in peak annual sales for DT120 in generalized anxiety disorder.
Insights by Ground AI
14 Articles
14 Articles
Coverage Details
Total News Sources14
Leaning Left2Leaning Right4Center5Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 18%
C 46%
R 36%
Factuality
To view factuality data please Upgrade to Premium
